secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2026-06-22T20:05:06+00:00
Accession:  0001193125-26-277506
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Spero Therapeutics' Utebzi, first oral carbapenem for cUTIs
------------------------------------------------------------------------

- Utebzi (tebipenem pivoxil) approved June 17, 2026 for complicated UTIs in adults with limited oral alternatives.
- PIVOT-PO trial showed 58.5% overall success vs 60.2% for IV imipenem-cilastatin (adjusted diff -1.3%).
- Most common AEs were diarrhea and headache; all mild/moderate and non-serious.
- GSK holds exclusive global license (excl. select Asia); BARDA supported development.
- Product anticipated to be available in US by end of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312526277506/0001193125-26-277506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312526277506/d51395d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-277506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer